Literature DB >> 22129889

Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.

Letizia Boninsegna1, Francesco Panzuto, Stefano Partelli, Paola Capelli, Gianfranco Delle Fave, Rossella Bettini, Paolo Pederzoli, Aldo Scarpa, Massimo Falconi.   

Abstract

INTRODUCTION: Malignant pancreatic neuroendocrine tumours (PNENs) are generally associated with a good prognosis after radical resection. In other pancreatic malignancies predictors of recurrence and the role of lymph node ratio (LNR) are well known, but both have been scarcely investigated for malignant PNETs.
METHODS: The prospective database from the surgical Department of Verona University was queried. Clinical and pathological data of all patients with resected malignant PNET between 1990 and 2008 were reviewed. Univariate and multivariate analysis were performed.
RESULTS: Fifty-seven patients (male/female ratio=1) with a median age of 58 years (33-78) entered in the study. Twenty-nine (51%) patients underwent pancreaticoduodenectomy and 28 (49%) distal pancreatectomy. Postoperative mortality was nil with a 37% morbidity rate. There were 36 (63%) patients with lymph node metastases (N1). Of these, 23 (64%) had a lymph node ratio (LNR) >0 and ≤0.20 and 13 (36%) had a LNR >0.20. The median overall survival and the median disease free survival (DFS) were 190 and 80 months, respectively. Recurrent disease was identified in 24 patients (42%) with a 2 and 5-year DFS rate of 82% and 49%, respectively. On multivariate analysis, LNR >0.20 (HR=2.75) and a value of Ki67 >5% (HR=3.39) were significant predictors of recurrence (P<0.02).
CONCLUSIONS: After resection for malignant PNETs, LNR and a Ki67 >5% are the most powerful predictors of recurrence. The presence of these factors should be considered for addressing patients to adjuvant treatment in future clinical trials.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129889     DOI: 10.1016/j.ejca.2011.10.030

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  52 in total

1.  Ectopic Adrenocorticotropic Hormone Syndrome Due to a Pancreatic Neuroendocrine Tumor.

Authors:  Meghana Bansal; Abhishek Agarwal; R Govindarajan
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 2.  Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.

Authors:  Marco Gallo; Pasqualino Malandrino; Giuseppe Fanciulli; Francesca Rota; Antongiulio Faggiano; Annamaria Colao
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-12       Impact factor: 4.553

Review 3.  Surgical resection of neuroendocrine tumors of the pancreas (pNETs) by minimally invasive surgery: the laparoscopic approach.

Authors:  Tomoki Shirota; Yuichi Nagakawa; Yatsuka Sahara; Chie Takishita; Yosuke Hijikata; Yuichi Hosokawa; Tetsushi Nakajima; Hiroaki Osakabe; Kenji Katsumata; Akihiko Tsuchida
Journal:  Gland Surg       Date:  2018-02

4.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

5.  Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors.

Authors:  Sven-Petter Haugvik; Irina Pavlik Marangos; Bård Ingvald Røsok; Ewa Pomianowska; Ivar Prydz Gladhaug; Oystein Mathisen; Bjørn Edwin
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

6.  Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified?

Authors:  Cornelius A Thiels; John R Bergquist; Danuel V Laan; Kristopher P Croome; Rory L Smoot; David M Nagorney; Geoffrey B Thompson; Michael L Kendrick; Michael B Farnell; Mark J Truty
Journal:  J Gastrointest Surg       Date:  2016-02-29       Impact factor: 3.452

7.  Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.

Authors:  Gabriele Carlinfante; Paola Baccarini; Debora Berretti; Tiziana Cassetti; Maurizio Cavina; Rita Conigliaro; Alessandro De Pellegrin; Luca Di Tommaso; Carlo Fabbri; Adele Fornelli; Andrea Frasoldati; Giorgio Gardini; Luisa Losi; Livia Maccio; Raffaele Manta; Nico Pagano; Romano Sassatelli; Silvia Serra; Lorenzo Camellini
Journal:  Virchows Arch       Date:  2014-05-08       Impact factor: 4.064

8.  Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

Authors:  Monica Ter-Minassian; Jennifer A Chan; Susanne M Hooshmand; Lauren K Brais; Anastassia Daskalova; Rachel Heafield; Laurie Buchanan; Zhi Rong Qian; Charles S Fuchs; Xihong Lin; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

9.  Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.

Authors:  Alessandro Zerbi; Vanessa Capitanio; Letizia Boninsegna; Gianfranco Delle Fave; Claudio Pasquali; Guido Rindi; Davide Campana; Massimo Falconi
Journal:  HPB (Oxford)       Date:  2013-03-08       Impact factor: 3.647

10.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.